Profile data is unavailable for this security.
About the company
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.
- Revenue in USD (TTM)0.00
- Net income in USD-19.26m
- Incorporated2019
- Employees18.00
- LocationDiaMedica Therapeutics Inc301 CARLSON PARKWAY, SUITE 210MINNEAPOLIS 55305United StatesUSA
- Phone+1 (763) 496-5454
- Fax+1 (763) 710-4456
- Websitehttps://www.diamedica.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunic Inc | 0.00 | -97.92m | 112.15m | 77.00 | -- | 1.34 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Nuvectis Pharma Inc | 0.00 | -22.38m | 112.89m | 13.00 | -- | 8.05 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7639 | 0.00 | -- | -- | 0.00 | -124.61 | -- | -170.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 114.53m | 20.00 | -- | 1.00 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.35m | 117.15m | 22.00 | -- | 1.30 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Cellectar Biosciences Inc | 0.00 | -50.98m | 118.30m | 20.00 | -- | 12.04 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| FibroGen Inc | 167.49m | -240.46m | 119.37m | 486.00 | -- | -- | -- | 0.7127 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 119.99m | 37.00 | -- | 0.9733 | -- | 115.12 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.26m | 120.35m | 18.00 | -- | 2.60 | -- | -- | -0.5532 | -0.5532 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -48.47 | -45.38 | -52.02 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Vor Biopharma Inc | 0.00 | -120.23m | 123.55m | 168.00 | -- | 1.00 | -- | -- | -1.78 | -1.78 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -54.09 | -45.79 | -57.42 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 124.45m | 384.00 | -- | 0.3834 | -- | 0.3127 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Allakos Inc | 0.00 | -214.44m | 127.50m | 131.00 | -- | 1.22 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| FitLife Brands Inc | 58.51m | 7.30m | 127.60m | 37.00 | 18.76 | 4.34 | 17.22 | 2.18 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Coya Therapeutics Inc | 6.13m | -10.30m | 127.62m | 8.00 | -- | 3.94 | -- | 20.82 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -43.89m | 128.01m | 25.00 | -- | 3.44 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -31.37m | 130.93m | 28.00 | -- | 1.22 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
Data as of May 17 2024. Currency figures normalised to DiaMedica Therapeutics Inc's reporting currency: US Dollar USD
11.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Apr 2024 | 1.02m | 2.68% |
| Omega Advisors, Inc.as of 31 Mar 2024 | 883.62k | 2.33% |
| First Manhattan Co LLCas of 31 Mar 2024 | 850.04k | 2.24% |
| Paragon JV Partners LLCas of 31 Mar 2024 | 500.00k | 1.32% |
| Geode Capital Management LLCas of 31 Mar 2024 | 239.24k | 0.63% |
| Bleichroeder LPas of 31 Mar 2024 | 222.32k | 0.59% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 209.33k | 0.55% |
| Jacob Asset Management of New York LLCas of 30 Sep 2023 | 168.73k | 0.45% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 109.34k | 0.29% |
| Aristides Capital LLCas of 31 Mar 2024 | 106.33k | 0.28% |
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
